[1] 张天泽, 徐光炜. 肿瘤学 [M]. 天津:天津科学技术出版社 1996.
[2] Berenson JR. The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain multiple myeloma [J]. Rer Contemp pharmacother 1998, 9(01).
[3] Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. [J]. Journal of Dental Research: Official Publication of the International Association for Dental Research 2007, 11(11).
[4] Rogers MJ, Gordon S, Benford HL. Cellular and molecular mechanisms of action of bisphosphonates [J]. Cancer 2000, 88(12s).
[5] Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. [J]. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 1998, 11(11).
[6] Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, Budillon A, Venuta S, Abbruzzese A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. [J]. Oncogene 2004, 41(41).
[7] Gouin F, Ory B, Redini F, Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. [J]. International Journal of Cancer 2006, 5(5). |
